CSC
APTO

Caldwell Sutter Capital’s Aptose Biosciences, Inc. APTO Stock Holding History

Caldwell Sutter Capital’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$327 Buy
202
+200
+10,000% +$324 ﹤0.01% 901
2026
Q1 		$3 Hold
2
– – ﹤0.01% 886
2025
Q4 		$3 Hold
2
– – ﹤0.01% 871
2025
Q3 		$2 Hold
2
– – ﹤0.01% 867
2025
Q2 		$2 Buy
+2
New +$3 ﹤0.01% 851
2025
Q1 		– Sell
-3
Closed -$21 – 925
2024
Q4 		$21 Hold
3
– – ﹤0.01% 886
2024
Q3 		$38 Hold
3
– – ﹤0.01% 892
2024
Q2 		$70 Hold
3
– – ﹤0.01% 900
2024
Q1 		$153 Hold
3
– – ﹤0.01% 889
2023
Q4 		$234 Hold
3
– – ﹤0.01% 913
2023
Q3 		$258 Hold
3
– – ﹤0.01% 847
2023
Q2 		$427 Buy
+3
New +$621 ﹤0.01% 830

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Caldwell Sutter Capital's APTO Position: Q2 2026 in Review

Caldwell Sutter Capital increased its Aptose Biosciences, Inc. (APTO) stake by 10,000% in Q2 2026, buying an estimated $324 and bringing the position to 202 shares worth $327. The position accounts for ﹤0.01% of the portfolio, ranked #901.

Caldwell Sutter Capital first reported a position in APTO in Q2 2023 and has held it in 12 quarters since. The position peaked at $427 in Q2 2023. 4 funds tracked by Wall St. Rank hold APTO as of Q2 2026.

  • Caldwell Sutter Capital held 202 shares of Aptose Biosciences, Inc. worth $327 as of Q2 2026.
  • Caldwell Sutter Capital bought 200 Aptose Biosciences, Inc. shares in Q2 2026, an estimated $324.
  • Aptose Biosciences, Inc. made up ﹤0.01% of Caldwell Sutter Capital's portfolio in Q2 2026, its #901 holding.
  • Caldwell Sutter Capital first reported a position in Aptose Biosciences, Inc. in Q2 2023 and has held it in 12 quarters since.
  • Caldwell Sutter Capital's Aptose Biosciences, Inc. position peaked at $427 in Q2 2023.
  • 4 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.